Skip to main content
. 2020 May 15;17(2):387–400. doi: 10.20892/j.issn.2095-3941.2019.0380

Figure 7.

Figure 7

The summary of DYRK1A in regulating Mcl-1 and anti-NSCLC effects of Bcl-2 inhibitors. DYRK1A promotes the stability of Mcl-1, and genetic or pharmacological inhibition of DYRK1A promotes the proteasome-dependent degradation of Mcl-1 in NSCLC cells. Mcl-1 overexpression confers acquired resistance to Bcl-2 inhibitors in NSCLC. Thus, DYRK1A suppression sensitizes NSCLC cells to Bcl-2 inhibitors treatment via regulating Mcl-1.